Delivery of EPC embedded in HA-hydrogels for treatment of acute kidney injury

Brian B. Ratliff* and Michael S. Goligorsky

Departments of Medicine, Pharmacology and Physiology; New York Medical College; Valhalla, NY USA

Keywords: endothelial progenitor cells, hyaluronic acid based hydrogels, stem cell therapy, acute kidney injury, endotoxemia, sepsis, Adriamycin-induced kidney injury

Abbreviations: AKI, acute kidney injury; EPC, endothelial progenitor cells; βFGF, beta fibroblast growth factor; HA, hyaluronic acid; HGH, human growth hormone; IFNγ, interferon gamma; IL, interleukin; IP-10, interferon gamma-induced protein 10; IRI, ischemia-reperfusion injury; IV, intravenous; LIF, leukemia inhibitory factor; LPS, lipopolysaccharide; MMP, matrix metalloproteinase; MSC, mesenchymal stem cells; PEGDA, polyethylene (glycol) diacrylate; RGD, arginine-glycine-aspartic acid sequence; SCF, stem cell factor; SDF-1, stromal-cell derived factor 1; VEGF, vascular endothelial growth factor

Adoptive transfer of stem cells has shown potential as an effective treatment for acute kidney injury (AKI). The current strategy for adoptive transfer of stem cells is by intravenous injection. However, this conventional method of stem cell delivery is riddled with problems causing reduced efficacy of the therapeutic potential of delivered stem cells. This review summarizes the recent advancements in an alternative method of stem cell delivery for treatment of AKI, embedding stem cells in hyaluronic acid (HA) based hydrogels followed by their implantation. Furthermore, one stem cell type in particular, endothelial progenitor cells (EPC), have shown remarkable therapeutic benefits for treatment of AKI when delivered by HA-hydrogels. The review also summarizes the delivery of EPC by HA-hydrogels in the setting of AKI.

Stem Cells for Therapeutic Use

While the potential of stem cells for tissue repair and regeneration in treatment of disease and injury has been subject to intense investigation over the past 20 years, the full therapeutic potential of these cells have yet to be fully realized. During this time, various stem cell lines have been isolated and characterized including embryonic and adult stem cells such as hematopoietic, mesenchymal, cardiac, neuronal and retinal. All these various stem cell lines have been examined for their therapeutic benefits including their adoptive transfer for treatment of injuries and diseases as diverse as post-chemotherapy blood disorders, myocardial infarction, burns, spinal cord and brain injuries, eye injury, diabetes, Crohn disease and muscular dystrophy, to name a few. The kidney has been no stranger to this ever expanding and evolving field. Stem cells have been demonstrated to possess a notable repair and regenerative potential when delivered to the injured kidney. However, currently much more advancement is needed before stem cell therapy is successfully applied clinically for broad scale use in the treatment of kidney disease.

One type of stem cells that has shown remarkable renoprotective potential without significant side effects are endothelial progenitor cells (EPC). EPC have been shown to improve renal function, attenuate the pro-inflammatory response associated with renal injury, and improve damage to tubules and renal vascular segments during kidney injury while providing enhanced neoangiogenesis. The beneficial attributes associated with EPC delivery for treatment of kidney damage counter the vascular impairment that occurs in the course of various episodes of acute kidney injury (AKI) that leads to the progressive nature of renal dysfunction and disease. An intact and healthy EPC niche, residing in the bone marrow but also found locally in renal vascular beds such as in the area of the adventitia layer of vessels, is relied on to maintain normal vascular function including maintenance and possible replacement of the endothelium.

The loss of EPC integrity during kidney disease was illustrated by our group in an Adriamycin model of nephropathy, in which the progressive nature of renal injury was heavily influenced by the destruction of competent endogenous EPC. The deterioration of the bone marrow EPC niche prevented both the mobilization of these cells to the sites of renal injury and ensuing repair of damage. When exogenous EPC were adoptively transferred, renal function considerably improved. These results are not exclusive to Adriamycin-induced nephropathy, but have also been seen in other models of AKI such as sepsis-induced AKI.

Problems with Current Methods of Cell Therapy: Treatment of AKI

One of the major problems confronting current stem cell (including EPC) therapy is the method for cell delivery. When stem cells are delivered by IV injection, less than 3% of the delivered cells find their way to the injured kidney and engraft, while majority of delivered cells undergo programmed cell death (anoikis) before they are capable of providing any therapeutic benefits to

*Correspondence to: Brian B. Ratliff; Email: ratliffbb@gmail.com
Submitted: 10/25/12; Revised: 12/13/12; Accepted: 12/14/12
Citation: Ratliff BB, Goligorsky MS. Delivery of EPC embedded in HA-hydrogels for treatment of acute kidney injury. Biomatter 2013; 3:e23284; http://dx.doi.org/10.4161/biom.23284

http://dx.doi.org/10.4161/biom.23284
damaged tissues.\textsuperscript{13} Many current trials examining the delivery of stem cells for treatment of kidney disease use IV injection of large quantities of cells (usually around 1 million cells per injection), administered all at once into the circulation by a bolus IV injection. Often times these delivered cells become trapped in the pulmonary vasculature causing embolism or suffer from anoikis before ever making it to the injured kidneys.\textsuperscript{13} Furthermore, if the impairment of kidney function is due to circulating factors such as cytotoxins, then stem cells introduced into the circulation by IV injection become susceptible to the harmful effects of such circulating toxins.

Another major problem with IV delivery of stem cells is related to integrin dependent activation and homing of delivered cells. While Β2 integrins are the major regulators of EPC transendothelial migration, integrins α5β1, α6β1, αvβ3 and αvβ5 are major determinants of EPC homing, invasion, differentiation and paracrine factor production with integrin α4β1 being a key regulator of EPC retention and/or mobilization from the bone marrow.\textsuperscript{14} The expression and activation of these integrins on the surface of stem cells is critical for their homing to proper sites of damage, adherence and exertion of their renoprotective paracrine influence.\textsuperscript{14} In essence, integrins give EPC a “guidance mechanism” to find their way around the circulation and locate the targeted damaged tissue. Furthermore, activation of integrins on the surface of EPC, and subsequent effects on intracellular cytoskeleton properties within the EPC, has also been shown to enhance the release of both anti-inflammatory and pro-regenerative substances\textsuperscript{14} from EPC enhancing their reparative capabilities. Integrins are activated once these cells bind to substrates that contain a RGD sequence (an arginine-glycine-aspartic acid conserved motif found in cell adhesion substrates such as fibronectin).\textsuperscript{15,16} When EPC are delivered by IV injection, because of the aqueous nature of both the delivery vehicle solution and the circulating plasma, delivered cells lack substrate RGD adherence cues that would trigger the expression and activation of integrins on their surface. The lack of integrin activation on delivered EPC prevents these cells from fully eliciting their protective effects. This presents yet another problem with conventional methods of IV delivery of cells.

**Bioengineered Scaffolds for Stem Cell Delivery: Treatment of AKI**

In attempt to protect delivered stem cells and to provide them with a microenvironment conducive to their viability while maximizing their therapeutic potential, our laboratory has experimented with the delivery of EPC embedded in bioengineered scaffolds. Scaffolds provide substantial flexibility because they can be constructed from many different substances and their properties chemically changed to allow for creation of alternative niche-like microenvironments. For instance, variable scaffold compositions can be manipulated to affect embedded stem cell retention, differentiation and proliferation while also influencing the release of anti-inflammatory molecules from embedded cells.\textsuperscript{17-19} The selection of specific biomaterial compositions for scaffold engineering can provide embedded cells with surroundings resembling the endogenous extracellular matrix\textsuperscript{20} and offer many advantages in regard to cell therapy applications. The use of such biomaterials allows for direct delivery and retention of EPC at the precise location of tissue damage leading to the improved delivery efficiency, a more intense therapeutic response, and avoidance of side effects related to systemic IV delivery.

Various bioengineered scaffolds have been constructed and tested for cell therapy purposes. For embedding of stem cells, it is highly desirable to create scaffolds that closely mimic the endogenous stem cell niche. Collagen, gelatin, fibrin, silk, agarose, alginate, dextran, cellulose, chitosan, heparin, chondroitin sulfate and hyaluronic acid engineered scaffolds are the more commonly and successfully used natural biomaterials for stem cell delivery in animal models.\textsuperscript{21-23} Recently, hyaluronic acid (HA) based hydrogels have emerged as a bioengineered scaffold that holds potential for its application in cell therapy. An advantage of stem cell delivery by embedding in HA-hydrogels is the ease of delivery. HA-hydrogels are implanted before their solidification, which allows for hydrogels with embedded cells to be delivered by a simple syringe injection. Once injected, the hydrogel concludes the solidification process within a few minutes. The delivery of HA-hydrogel scaffolds (without embedded cells) composed of thiol-modified gelatin (derived from collagen I and IV) results in the least inflammatory response, as compared with various other bioengineered scaffolds.\textsuperscript{24} In experiments by our lab, we observed greatest response from embedded EPC when pronectin (50 mg/ml) was added to these denatured collagen HA-hydrogels and crosslinked at 4% with polyethylene (glycol) diacrylate (PEGDA).\textsuperscript{7} Addition of pronectin introduced the critical RGD binding element required by EPC for adhesion and activation of cell surface integrins including α5β1, α6β1, αvβ3, αvβ5 and α4β1.\textsuperscript{14} The use of 4% PEGDA crosslinker provides optimal hydrogel rigidity and permits significant cell retention and viability while preventing infiltration of toxins present in the external milieu.\textsuperscript{7}

An advantage of HA-hydrogels is their ability to be readily dissolved on demand. Since the main constituents of hydrogels are denatured collagen and HA, these scaffolds can easily and rapidly be dissolved with hyaluronidase and collagenase, subsequently allowing the release and mobilization of embedded stem cells. Used in the correct concentrations, these digesting enzymes do not cause damage or phenotypical change to embedded cells.\textsuperscript{7} The application of digesting enzymes is simple and consists of a mere injection directly into the implanted HA-hydrogel, followed by dissolution of the gel and complete mobilization of embedded cells within 24–48 h.\textsuperscript{7} The ability to release embedded EPC on demand provides greater flexibility of cell therapy. For instance, HA-hydrogels with embedded EPC can be implanted into desired tissues where they remain until the release of EPC is required for local tissue repair. Meanwhile, the considerable retention of EPC in HA-hydrogels means embedded cells will stay in their implant locality (usually up to two weeks), while retaining their capability to secrete anti-inflammatory and pro-angiogenic molecules that can escape the scaffolding into the surrounding tissue and circulation.\textsuperscript{25-27} The ability to regulate the release of EPC from implanted scaffolds also allows flexibility in the timing of hydrogel implantation for treatment of kidney injury. The kidney is especially
useful for HA-hydrogel delivery of stem cells because during kidney injury, the injured tissue endogenously releases hyaluronidase. The intrinsic release of hyaluronidase means the kidney, when injured, will automatically digest implanted HA-hydrogels even without injection of enzymes, allowing release of embedded stem cells. Since hyaluronidase is released when kidneys are initially injured, the digestion of HA-hydrogels and subsequent EPC release occurs at an optimal time during kidney injury allowing for EPC therapeutic effects to engage before damage becomes too extensive and irreparable. A schematic summary of the implantation of HA-hydrogels and subsequent release and mobilization of embedded EPC for treatment of AKI is provided in Figure 1.

In studies by our lab, we have conducted multiple experiments using HA-hydrogels as a bioengineered scaffold for delivery of stem cells (EPC) for the treatment of various forms of AKI (the results of these experiments are summarized in Tables 1 and 2). The first AKI model we examined was a model of Adriamycin (doxorubicin) induced nephropathy, which is characterized by tubulointerstitial damage, glomerulosclerosis with accompanying glomerular visceral epithelial cell damage and proteinuria. In preliminary in vitro experiments, we first assessed if HA-hydrogel scaffolds offered protection to embedded EPC against toxins such as Adriamycin. Indeed, at concentrations of Adriamycin (1–50 μM) that normally caused cell damage and death, HA-hydrogel embedding protected cells against cytotoxicity and resulted in 6-fold enhanced cell viability of EPC. This effect was primarily the result of the impediment for toxins to readily infiltrate the HA-hydrogel and damage embedded EPC. In a murine in vivo model, HA-hydrogels with embedded EPC were delivered to Adriamycin-induced AKI mice. In these in vivo experiments, HA-hydrogels were implanted at two locations, subcutaneously in the ear (for ease of microscopic monitoring of fluorescently labeled embedded cells) and supcapsularly in the kidney. While HA-hydrogels were implanted prior to Adriamycin-induced AKI, EPC were not released from these scaffolds until after administration of Adriamycin. Embedded EPC were released into the systemic circulation from ear implanted HA-hydrogels by direct injection of digestive enzymes within 1–2 h after Adriamycin administration. HA-hydrogels implanted in the kidney were digested by endogenous renally secreted hyaluronidase allowing for release of embedded EPC locally into the injured kidney. Adoptive transfer of EPC into mice with Adriamycin-induced AKI reduced both short- and long-term elevation in serum creatinine levels by 50–60% and long-term proteinuria by 60–75%, with greater improvement observed with EPC delivery by HA-hydrogel as compared with IV injection. Engraftment of EPC into the damaged kidney was enhanced by as much as 6-fold when EPC were delivered by HA-hydrogel as opposed to IV delivery. Only slight differences were observed when HA-hydrogels were implanted in the ear as compared with the kidney. These differences included increased renal engraftment of EPC when HA-hydrogels were implanted in the kidney while ear implants and subsequent EPC release resulted in a slightly better improvement of systemic functions, such as blood pressure.

We further examined the effects of EPC delivery by HA-hydrogel to determine if the enhanced therapeutic effect of these bioengineered scaffolds was applicable to other kidney injury...
models in addition to Adriamycin nephropathy. In a mouse renal ischemia-reperfusion injury (IRI) model of AKI, in which renal blood flow was occluded for 30 min causing microcirculatory and tubular damage, the delivery of EPC by HA-hydrogel resulted in 50% attenuation of the associated rise in serum creatinine 36 h post-IRI, demonstrating the beneficial effects of HA-hydrogel delivery of EPC are not limited to Adriamycin-induced AKI. Improvements in various systemic and local parameters during sepsis- and Adriamycin-induced AKI after treatment by adoptive transfer of EPC by either conventional IV delivery or implantation of HA-hydrogels with embedded EPC.

| Parameter                        | IV delivery | HA-hydrogel delivery |
|----------------------------------|-------------|-----------------------|
| Mean blood pressure              | ++          | +++                   |
| Hepatic enzymes (ALT and AST)    | +           | +++                   |
| Bone marrow EPC colony forming ability | ++          | +++                   |
| Serum creatinine                 | ++          | +++                   |
| Intrarenal microcirculation      | ++          | +++                   |
| EPC engraftment                  | +           | +++                   |
| Cytokines/chemokines             | ++          | +++                   |
| Proteinuria                      | ++          | +++                   |
| Long-term fibrosis               | +++         | +++                   |

All parameters were measured 18–36 h after induction of AKI, except long-term proteinuria and fibrosis, which were measured 3 weeks and 2 mo, respectively, after AKI induction. + denotes improvement.

The improvement in the therapeutic efficacy of adoptive transfer of EPC by HA-hydrogel delivery prompted us to examine the effects of this phenomenon more elaborately in another model of AKI. Endotoxemia and related sepsis is a growing health problem in our society today and is a significant contributor to AKI. During sepsis, circulating endotoxins cause damage to the vascular endothelium and promote a catalytic immune system response that involves substantial release of chemokines and cytokines causing multiple organ damage including AKI. Since sepsis-induced AKI is a result of microvascular damage and the immune response, the ability of EPC to mediate both vascular repair/regeneration while also modulating the immune response makes these stem/progenitor cells attractive candidates for cell therapy of this form of AKI. A critical effect that occurs during sepsis is that intrinsic EPC niches and reparative stem cell pools are adversely affected by circulating endotoxins including loss of endogenous EPC competence, integrity and viability leading to the inability of these stem cells to mediate vascular and renal repair and regeneration. While adoptive transfer of EPC is an attractive approach to combat sepsis-induced AKI, conventional IV delivery of these cells is problematic because once EPC are introduced into the circulation, they are predisposed to damage due to their exposure to the circulating endotoxins initially responsible for both systemic and local tissue damage.

Similar to our studies on Adriamycin, HA-hydrogels protected embedded EPC from the endotoxin LPS in vitro experiments. In vivo studies, adoptive transfer of EPC to septic mice improved systemic functions within 24 h after injection of LPS. Sepsis is typically characterized by hypotension and elevation of circulating hepatic enzymes. EPC delivery by IV injection significantly improved arterial blood pressure and reduced hepatic release of ALT and AST, however, EPC delivery by HA-hydrogel completely normalized both blood pressure and hepatic enzyme release to healthy baseline levels. EPC adoptive transfer also afforded renoprotection, both short- and long-term during sepsis. Improved systemic functions within 24 h after injection of LPS. IV administration of EPC improved renal blood flow, both cortical and medullary, by 40% and 22%, respectively; however, this improvement was markedly potentiated to 75% and 56% when EPC were delivered by HA-hydrogel. In addition to improving renal microcirculation, renal function (as measured by serum creatinine) was improved by 55% upon HA-hydrogel EPC delivery. In long-term studies, EPC delivery by HA-hydrogel cut in half the renal interstitial fibrosis that was associated with sepsis-induced AKI and endogenous bone marrow EPC competence was restored. While adoptive transfer of EPC in general led to improvement of all sepsis-induced systemic and renal abnormalities, the therapeutic ability of EPC was greatly enhanced (both short- and long-term) when these cells were delivered by HA-hydrogel scaffolding. The duration of a latent period before cells are released from the implanted HA-hydrogel scaffold and become exposed to the circulating endotoxins represents the major difference between the adoptive transfer of cells via HA-hydrogel vs. IV delivery.

In the latest series of hydrogel experiments by our lab, we have combined delivery of EPC with renal mesenchymal stem cells (MSC). Our lab has previously isolated MSC from the murine kidney. These MSC are positive for typical stem cell markers such as Sca-1, CD29, CD44, CD73, negative for CD117 and CD45, and are able to differentiate into multiple cell lineages including chondrocytes, osteocytes and adipocytes. Intrinsic stem cell niches, such as in bone marrow and in cardiac tissue, contain multiple progenitor cell types and lineage committed cells which serve as supporting cells for the niche. Supporting cells help maintain the quality and stability of the niche and play a role in asymmetric stem cell division and renewal of daughter cells. Introducing renal MSC into HA-hydrogels to support EPC may improve the quality of the bioartificial niche and enhance the regenerative response of the embedded cells. MSC are especially attractive candidates for the supporting cell role because they have been reported to improve stem cell niche quality and stem cell mobilization and homing through release of SDF-1, SCF and LIF. MSC also possess immuno-modulatory properties due to their release of anti-inflammatory molecules, such as IL-10, and...
may be particularly true for MSC which are capable of abundant release of anti-inflammatory and pro-angiogenic paracrine molecules such IL-10, IFN-γ and IP-10, to name a few. The reduction of the pro-inflammatory response that accompanies sepsis may in large part mediate the improvement in systemic hemodynamics, renal microcirculation and endothelial integrity, factors that all improve renal function. While HA-hydrogel embedded EPC are protected from circulating endotoxins, these cells are still able to secrete anti-inflammatory and pro-angiogenic molecules that can escape the scaffolding into the surrounding tissue and circulation thereby eliciting a pro-reparative effect. This may be particularly true for MSC which are capable of abundant release of anti-inflammatory and pro-angiogenic paracrine molecules such IL-10, IL-8, IP-10, MMP’s and various growth factors including VEGF, bFGF and HGH.

**Conclusions**

EPC delivery in bioengineered scaffolds, such HA-hydrogels, offers significant advantages over conventional cell delivery by...
IV injection. Proenectin-coated HA-hydrogels closely resemble endogenous stem cell niches and thus provide a microenvironment conducive for viability and expansion of embedded cells while also providing protection from circulating cyto- and endothelial toxins. HA-hydrogels are readily implantable within tissues and organs, including the kidney. The composition of HA-hydrogels allows them to be easily dissolved on demand permitting mobilization of embedded cells. In experiments using multiple models of AKI, the use of HA-hydrogels for delivery of EPC enhances the therapeutic efficacy of these stem cells by providing substantial systemic and renal protective effects. The enhanced therapeutic performance of HA-hydrogel embedded EPC is the result of multiple factors. Increased cellular α4β1 integrin binding to RGD sequences present in HA-hydrogels activate EPC causing potentiated release of anti-inflammatory and pro-angiogenic molecules, engraftment and transdifferentiation. Despite current advancements, continued development of the adoptive transfer of EPC by HA-hydrogel delivery is needed before its application is clinically realized for treatment of AKI.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
Studies from the authors’ laboratories were supported in part by the grants from the AHA 12SDG9080006 (BBR) and NIH DK54602, DK052783, DK45462 and Westchester Artificial Kidney Foundation (MSG).

References
1. Baddour JA, Sousounis K, Tsonis PA. Organ repair and regeneration. Birth Defects Res C Embryol Today 2012; 96:1-29; PMID:22457174; http://dx.doi.org/10.1002/bdre.21006.
2. Ghaly T, Rabadi MM, Weber M, Rabadi SM, Bank M, Grom JM, et al. Hydrogel-embedded endothelial progenitor cells evade LPS and mitigate endotoxicemia. Am J Physiol Renal Physiol 2011; 301:F802-12; PMID:21775481; http://dx.doi.org/10.1152/ajprenal.00124.2011.
3. Kale S, Karhaloo A, Clark PR, Kashgarian M, Krause CN, Canley LG. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest 2003; 112:42-9; PMID:12824456.
4. Park HC, Yasuda K, Ratliff B, Stoessel A, Sharkovska H, Hatzopoulos AK. The use of stem and endothelial progenitor cells in acute and chronic renal failure. Transl Res 2010; 156:227-32; PMID:20410213; http://dx.doi.org/10.1016/j.trsl.2010.07.005.
5. Pothnick D, Ploetkin M, Goligrory MS. Therapeutic use of stem and endothelial progenitor cells in acute renal injury: a era. Curr Opin Pharmacol 2006; 6:167-83; PMID:16487748; http://dx.doi.org/10.1016/j.coph.2005.10.013.
6. Pino CJ, Humes HD. Stem cell technology for the kidney. J Am Physiol Renal Physiol 2010; 298:F357-64; PMID:19960947; http://dx.doi.org/10.1152/ajprenal.00542.2009.
7. Potschke D, Plotkin M, Goligrory MS. Therapeutic use of stem and endothelial progenitor cells in acute renal injury: a era. Curr Opin Pharmacol 2006; 6:167-83; PMID:16487748; http://dx.doi.org/10.1016/j.coph.2005.10.013.
8. Yasuda K, Park HC, Ratliff B, Stoessel A, Sharkovska H, Hatzopoulos AK. The use of stem and endothelial progenitor cells in acute and chronic renal failure. Transl Res 2010; 156:227-32; PMID:20410213; http://dx.doi.org/10.1016/j.trsl.2010.07.005.
9. Ratliff BB, Ghaly T, Bruudnick P; Yasuda K, Rajdev M, Bank M, et al. Endothelial progenitor encapsulated in bioartificial niches are insulated from systemic cytotoxicity and are angiogenesis competent. Am J Physiol Renal Physiol 2010; 299:F178-86; PMID:20410213; http://dx.doi.org/10.1152/ajprenal.00124.2011.
10. Yasuda K, Park HC, Ratliff B, Addabfo F, Hatzopoulos AK, Chandler P, et al. Adriamycin nephropathy: a failure of endothelial progenitor cell-induced repair. Am J Pathol 2010; 176:1685-95; PMID:20167859; http://dx.doi.org/10.2215/ajpath.130.9.1685.
11. Goligrory MS, Yasuda K, Ratliff B. Dysfunctional endothelial progenitor cells in chronic kidney disease. J Am Soc Nephrol 2010; 21:911-9; PMID:20393371; http://dx.doi.org/10.1681/ASN.2009111117.
12. Aksara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1999; 275:964-7; PMID:9203076; http://dx.doi.org/10.1126/science.275.5626.
13. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000; 97:342-7; PMID:10725398; http://dx.doi.org/10.1073/pnas.97.3422.40
42. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012; 10:244-58; PMID:22385653; http://dx.doi.org/10.1016/j.stem.2012.02.005.

43. Gao J, Liu R, Wu J, Liu Z, Li J, Zhou J, et al. The use of chitosan based hydrogel for enhancing the therapeutic benefits of adipose-derived MSCs for acute kidney injury. Biomaterials 2012; 33:3673-81; PMID:22361096; http://dx.doi.org/10.1016/j.biomaterials.2012.01.061.
In July of 2011 we launched *Biomatter*, an international and transdisciplinary journal for the publication of peer-reviewed, original research exploring the clinical and laboratory investigations in the field of science and application of biomaterials. The journal covers all applications of biomaterials, including implantable medical devices, drug delivery systems, nanomedicine, tissue engineering and regenerative medicine as well as all types of synthetic and natural biomaterials (metals, ceramics, polymers and composites) used for biomedical applications.

http://www.landesbioscience.com/journals/biomatter

*Biomatter* publishes original articles, review articles, short communications and letters to the Editor.

**The Editors undertake to provide a decision 30 days following submission. Submit your paper online:** http://biomatter.msubmit.net

---

**Editorial Board**

| Arti Ahluwalia | Hakan Engqvist | C. James Kirkpatrick |
|---------------|----------------|---------------------|
| Morgan Alexander | Milena Fini | Kuen-Yong Lee |
| Luigi Ambrosio | Dirk W. Grippma | Didier Letourneur |
| Joelle Amédée | Zhongwei Gu | Changhai Liu |
| Stelios T. Andreasis | Pamela Habibovic | Matthias P. Lutolf |
| José Luis Arias | Takao Hanawa | Takuya Matsumoto |
| Kyriacos A. Athanasiou | Allan S. Hoffman | David J. Mooney |
| Frank P.T. Baaijens | Kazuhiko Ishihara | William L. Murphy |
| Mário A. Barbosa | Suwan Jayasinghe | Mitsuo Niinomi |
| Smadar Cohen | Jian Ji | Alyssa Panitch |
| Paolo Di Nardo | Xiabin Jing | Jae Hyung Park |
| Jiandong Ding | Ali Khademhosseini | Glenn D. Prestwich |
| Jennifer H. Elisseeff | Soo Hyun Kim | Suzie H. Pun |
| | | | Stefan Rammelt |
| | | | Buddy D. Ratner |
| | | | Rui L. Reis |
| | | | José Carlos Rodriguez-Cabello |
| | | | J. Paul Santerre |
| | | | Hélider A. Santos |
| | | | Alexander M. Seifalian |
| | | | Lonnie D. Shea |
| | | | Molly S. Shoichet |
| | | | Molly M. Stevens |
| | | | Carsten Werner |
| | | | Joyce Y. Wong |
| | | | Masayuki Yamato |

---

**Notes to Potential Authors**

- Open access charges are waived until the Volume 3, Issue 3 (July/August/September 2013).
- Accepted manuscripts will be published on the website within three weeks.
- For additional information please review our submission guidelines: http://www.landesbioscience.com/journals/biomatter/guidelines
- Questions? Contact the Editor-in-Chief, Pedro L. Granja (pgranja@ineb.up.pt) or the Managing Editor, Liz Gilmer (biomatter@landesbioscience.com).

To submit a manuscript to *Biomatter*, please visit http://biomatter.msubmit.net